TIDES Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Discovery and clinical development at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
32 organizations at TIDES Europe 2026 present work in discovery & clinical: 25 drug developers, 4 suppliers and service providers and 3 academic, government and non-profit bodies. Between them they bring 51 presentations to the program. Most represented: Novo Nordisk (6 on the program), Eli Lilly and Company (4 on the program), AstraZeneca (4 on the program). As of Nov 2, 2026.
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company known for diabetes and obesity medicines, including the GLP-1 peptide drugs semaglutide and liraglutide. | Keynote Tue Nov 3 13:50–14:25 Next Generation GLP-1 Therapeutics How GLP-1 drugs for metabolic disease became longer-acting, and what it would take to dose them less often or swallow them as pills. PeptidesObesity & Metabolic Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. Talk Thu Nov 5 09:05–09:35 Identity Testing of Synthetic Peptides: From Multi-Method Evaluation to a Compliant Two-Test Scheme Why two well-chosen laboratory tests can prove a manufactured peptide is the intended molecule, rather than the longer list of tests regulators expect. Talk Thu Nov 5 08:35–09:05 siRNA Conjugate Mediated Delivery to Disease Specific Cell Types Occurs through a Novel Mechanism How siRNA drugs attached to a carrier reach the cells behind chronic inflammatory disease and cancer, and how that route was worked out. Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. Talk Fri Nov 6 08:40–09:10 Keynote Presentation: Decoding The Future of Obesity Care: The Signals Worth Paying Attention To Where obesity drug development stands in 2026 and which companies and market openings across Europe are worth watching. Talk Fri Nov 6 11:40–12:05 |
Eli Lilly and Company Indianapolis, IN | |
Global pharmaceutical company whose peptide medicines include tirzepatide, with programs in oligonucleotide therapeutics. | Keynote Tue Nov 3 13:15–13:50 Making Oligonucleotides a High-Volume Reality: Next-Gen Platforms and Strategy for Oligonucleotide Manufacturing OligonucleotidesCMC & Manufacturing Keynote Tue Nov 3 14:25–15:00 Retatrutide: From Breakthrough Science to Global Medicine — The CMC Story Behind a Novel GIP, GLP-1, and Glucagon Receptor Agonist How the obesity and diabetes drug retatrutide is made at world supply scale by joining peptide fragments in solution with far less waste. PeptidesCMC & Manufacturing Talk Wed Nov 4 16:45–17:15 Made to Scale: What Tirzepatide's Manufacturing Challenge Teaches Us About Innovation Under Pressure Lessons from scaling up production of the diabetes and obesity drug tirzepatide, from an odd result at the bench to tonnes of material. Chair Thu Nov 5 08:00–08:05 Talk Thu Nov 5 16:00–16:30 Cycle Time Is a Quality Metric: Eloralintide from Discovery to Clinical Proof of Concept How the peptide eloralintide moved from discovery into patients by overlapping chemistry and biology cycles instead of running them one after another. |
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing medicines across modalities, including oligonucleotide and peptide therapeutics. | Talk Thu Nov 5 15:00–15:30 Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development Why purifying siRNA can quietly shift the mix of mirror-image sulfur linkages between batches, and how to keep that mix steady. Talk Thu Nov 5 09:05–09:35 Peptide-Targeted Delivery of Oligonucleotide Therapeutics Early, pre-clinical work on a short peptide that steers gene-silencing drugs into the tissue where they are meant to act. Talk Thu Nov 5 09:05–09:35 Rethinking Green Credentials for Oligo Manufacturing Why simple waste-per-kilogram scores misjudge how green oligonucleotide production is, and what real improvement would involve. Talk Thu Nov 5 08:35–09:05 Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition A way to choose where to split a long peptide into fragments so it can be built in solution with better yield. |
Alnylam Pharmaceuticals Cambridge, MA | |
Develops and markets RNA interference (RNAi) therapeutics, including GalNAc-conjugated siRNA medicines for genetic, cardiometabolic and other diseases. | Talk Thu Nov 5 15:00–15:30 Genetically Validated Targets and the Next Wave of RNAi Therapeutics: Progress from the Alnylam Pipeline Progress in gene-silencing medicines at one company, including how human genetics points to new targets and what a broad pipeline has taught them. Talk Thu Nov 5 10:45–11:25 Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies. |
European Medicines Agency Amsterdam, Netherlands | |
European Union agency that evaluates and supervises medicines, including oligonucleotide and peptide products. | Talk Wed Nov 4 15:00–15:30 EMA Perspectives on mRNA Vaccines and Therapeutics Where European regulators stand on quality rules for mRNA vaccines and medicines, and which problems keep coming up in applications. Talk Wed Nov 4 09:05–09:35 Regulatory Landscape for Synthetic Peptides and Oligonucleotides: EMA Insights and Guideline Updates An update on two draft European guidelines for synthetic peptides and oligonucleotides, the feedback they drew and the problems seen in filings. |
Wave Life Sciences Cambridge, Massachusetts | |
Develops stereopure oligonucleotide medicines, including siRNA, antisense and RNA editing candidates. | Talk Wed Nov 4 09:05–09:35 Applying Small Molecule Drug Design Principles to Improve the Drug-like Properties of siRNA Designing siRNA the way chemists design small-molecule drugs, controlling each linkage to get lasting gene silencing in mouse liver and kidney. Talk Thu Nov 5 16:30–17:00 Synthesis and Characterization of Stereopure Chimeric Oligonucleotides Making and testing oligonucleotides in which every backbone link has one fixed mirror-image form, in small batches, to link structure to activity. |
Consultancy working on oligonucleotide chemistry, manufacturing and controls from the early discovery stage onward. | Talk Tue Nov 3 09:10–09:45 Drug Substance and Drug Product and How CMC Early in the Discovery Lifecycle Can Help Why a careful handover from making the drug substance to making the finished product makes the paperwork for first clinical trials easier. Chair Thu Nov 5 13:55–14:00 |
NT noctuRNA Therapeutics Barcelona, Spain | |
Pompeu Fabra University spin-off developing circular RNA therapeutics for infectious, neuromuscular and neurodegenerative diseases. | Chair Wed Nov 4 13:55–14:00 Talk Wed Nov 4 16:45–17:15 Novel Circular RNA Therapeutics for Infectious and Non-infectious Diseases Engineered circular RNA that grabs onto folded, disease-causing RNA, tested in amyotrophic lateral sclerosis, myotonic dystrophy and viral infection. |
SM Sheba Medical Center Ramat Gan, Israel | |
Israeli teaching hospital in Ramat Gan whose N=1 program makes individually tailored antisense drugs for patients with rare diseases. | Chair Thu Nov 5 13:55–14:00 Talk Thu Nov 5 17:00–17:30 Overcoming the Cost Bottleneck in N=1 Therapeutics: A Highly Affordable, GMP-Compliant CMC Platform for Rapid Clinical Deployment A cheaper, standardised way to make a one-patient antisense drug under regulated manufacturing rules, used for a child with a rare brain disorder. |
Silence Therapeutics London, United Kingdom | |
Develops siRNA medicines using its mRNAi GOLD platform for cardiovascular, haematological and other diseases. | Talk Wed Nov 4 10:15–10:45 Elongating siRNA Duration of Action by Enhanced Nuclease Resistance: End Stabilization Revisited A modification near each end of a siRNA made gene silencing in mice last longer while needing fewer sulfur linkages. |
Spatial biology tools built on RNAscope in situ hybridization and the COMET system: reagents, instruments and software for RNA and protein detection. | Booth Exhibiting at Booth K8 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 12:50–13:10 Spatially Resolving RNA Therapeutics in Heterogenous Organs: RNAscope to Correlate Biodistribution and Efficacy at Single-Cell Resolution How a tissue staining method shows which individual cells take up an RNA drug and whether it changes gene activity there. OligonucleotidesDiscovery & Clinical |
Catalent Somerset, NJ | |
Contract development and manufacturing organization for drug products, including oral delivery technologies and injectable formulation and fill-finish. | Booth Exhibiting (no floor booth listed) Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 12:30–12:50 Advancing Beyond Injections: Technologies Driving Oral Delivery of Peptides Ways to get peptide drugs absorbed when swallowed rather than injected, using fatty carriers, slow-release capsules and the lining of the mouth. PeptidesDiscovery & Clinical |
Find buyers in discovery & clinical
Tell us what you sell and we’ll find the people at organizations working on discovery & clinical most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse TIDES Europe 2026 by
- Oligonucleotides 73
- Peptides 35
- CMC & Manufacturing 59
- Discovery & Clinical 32
- Obesity & Metabolic 13
Not affiliated with or endorsed by TIDES Europe or its organizers. Submit a correction